Qianhui Yi

Supplementary Data from Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

Supplementary figures and methods

SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain

Qianhui Yi, Xiaojun Han, Henry Yu, Huei-Yu Chen et autres

ca (code pays fourni par la source)

RETRACTED: SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain

Jian Wu, Qianhui Yi, Xiaojun Han, Henry Yu et autres

Abstract The authors have requested that this preprint be removed from Research Square.

ca, my (code pays fourni par la source)

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

The current mainstay therapeutic strategy for advanced prostate cancer is to suppress androgen receptor (AR) signaling. However, castration-resistant prostate cancer (CRPC) invariably arises with restored AR signaling activity. To date, the AR ligand-binding domain (LBD) is the only targeted region for all …

ca, us (code pays fourni par la source)

Supplementary Data from Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

Supplementary figures and methods

Data from Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

Abstract The current mainstay therapeutic strategy for advanced prostate cancer is to suppress androgen receptor (AR) signaling. However, castration-resistant prostate cancer (CRPC) invariably arises with restored AR signaling activity. To date, the AR ligand-binding domain (LBD) is the only targeted region for …

Data from Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

Abstract The current mainstay therapeutic strategy for advanced prostate cancer is to suppress androgen receptor (AR) signaling. However, castration-resistant prostate cancer (CRPC) invariably arises with restored AR signaling activity. To date, the AR ligand-binding domain (LBD) is the only targeted region for …

Supplementary Data from Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su et autres

Supplementary figures and methods

Discovery of small-molecule AR-V7 inhibitor for castration-resistant prostate cancer

Qianhui Yi

Le cancer de la prostate résistant à la castration (CRPC) est une forme récidivante du cancer de la prostate des thérapies initiales de privation d'androgènes (ADT), sa progression manifeste une activité de signalisation des récepteurs aux androgènes (AR) réactivée malgré le niveau …

Investigation of the transcription factor GATA2 as a potential therapeutic target for castration-resistance prostate cancer

Qianhui Yi

The androgen receptor (AR) serves as a key driver of the proliferation and survival of prostate cancer (PCa) cells. Current mainstay treatment is to block the AR signaling by androgen deprivation therapy and antiandrogens. Despite the short-term efficacy of suppressing AR signaling, …